Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients

Monte S. Buchsbaum, Eric Hollander, Stefano Pallanti, Nicolò Baldini Rossi, Jimcy Platholi, Randall Newmark, Rachel Bloom, Erica Sood

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We studied 15 nondepressed patients with obsessive-compulsive disorder (OCD) who were nonresponders to serotonin reuptake inhibitors with an additive trial of risperidone. Positron emission tomography with 18F- deoxyglucose and magnetic resonance imaging was obtained at baseline and following 8 weeks of either risperidone or placebo in a double-blind parallel group design. Risperidone treatment was associated with significant increases in relative metabolic rate in the striatum, cingulate gyrus, the prefrontal cortex, especially in the orbital region, and the thalamus. Four of 9 patients who received risperidone showed clinical improvement (CGI score of 1 or 2 at 8 weeks) while none of the 6 patients who received placebo showed improvement. Patients with low relative metabolic rates in the striatum and high relative metabolic rates in the anterior cingulate gyrus were more likely to show a clinical response. These metabolic predictors of clinical response are consistent with earlier PET studies showing similar prediction when either neuroleptics or serotonin reuptake inhibitor treatments are administered individually. Our results are consistent with a frontostriatal circuit change related to both dopaminergic and serotonergic systems and with the presence of psychopharmacological subtypes within OCD.

Original languageEnglish (US)
Pages (from-to)157-168
Number of pages12
JournalNeuropsychobiology
Volume53
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Risperidone
Serotonin Uptake Inhibitors
Positron-Emission Tomography
Obsessive-Compulsive Disorder
Gyrus Cinguli
Placebos
Deoxyglucose
Prefrontal Cortex
Thalamus
Antipsychotic Agents
Magnetic Resonance Imaging
Therapeutics

Keywords

  • F-deoxyglucose
  • Caudate
  • Cingulate gyrus
  • Obsessive-compulsive disorder
  • Putamen

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. / Buchsbaum, Monte S.; Hollander, Eric; Pallanti, Stefano; Rossi, Nicolò Baldini; Platholi, Jimcy; Newmark, Randall; Bloom, Rachel; Sood, Erica.

In: Neuropsychobiology, Vol. 53, No. 3, 06.2006, p. 157-168.

Research output: Contribution to journalArticle

Buchsbaum, MS, Hollander, E, Pallanti, S, Rossi, NB, Platholi, J, Newmark, R, Bloom, R & Sood, E 2006, 'Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients', Neuropsychobiology, vol. 53, no. 3, pp. 157-168. https://doi.org/10.1159/000093342
Buchsbaum, Monte S. ; Hollander, Eric ; Pallanti, Stefano ; Rossi, Nicolò Baldini ; Platholi, Jimcy ; Newmark, Randall ; Bloom, Rachel ; Sood, Erica. / Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. In: Neuropsychobiology. 2006 ; Vol. 53, No. 3. pp. 157-168.
@article{cc5e512c79f84976adaf719a8b43cb6e,
title = "Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients",
abstract = "We studied 15 nondepressed patients with obsessive-compulsive disorder (OCD) who were nonresponders to serotonin reuptake inhibitors with an additive trial of risperidone. Positron emission tomography with 18F- deoxyglucose and magnetic resonance imaging was obtained at baseline and following 8 weeks of either risperidone or placebo in a double-blind parallel group design. Risperidone treatment was associated with significant increases in relative metabolic rate in the striatum, cingulate gyrus, the prefrontal cortex, especially in the orbital region, and the thalamus. Four of 9 patients who received risperidone showed clinical improvement (CGI score of 1 or 2 at 8 weeks) while none of the 6 patients who received placebo showed improvement. Patients with low relative metabolic rates in the striatum and high relative metabolic rates in the anterior cingulate gyrus were more likely to show a clinical response. These metabolic predictors of clinical response are consistent with earlier PET studies showing similar prediction when either neuroleptics or serotonin reuptake inhibitor treatments are administered individually. Our results are consistent with a frontostriatal circuit change related to both dopaminergic and serotonergic systems and with the presence of psychopharmacological subtypes within OCD.",
keywords = "F-deoxyglucose, Caudate, Cingulate gyrus, Obsessive-compulsive disorder, Putamen",
author = "Buchsbaum, {Monte S.} and Eric Hollander and Stefano Pallanti and Rossi, {Nicol{\`o} Baldini} and Jimcy Platholi and Randall Newmark and Rachel Bloom and Erica Sood",
year = "2006",
month = "6",
doi = "10.1159/000093342",
language = "English (US)",
volume = "53",
pages = "157--168",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients

AU - Buchsbaum, Monte S.

AU - Hollander, Eric

AU - Pallanti, Stefano

AU - Rossi, Nicolò Baldini

AU - Platholi, Jimcy

AU - Newmark, Randall

AU - Bloom, Rachel

AU - Sood, Erica

PY - 2006/6

Y1 - 2006/6

N2 - We studied 15 nondepressed patients with obsessive-compulsive disorder (OCD) who were nonresponders to serotonin reuptake inhibitors with an additive trial of risperidone. Positron emission tomography with 18F- deoxyglucose and magnetic resonance imaging was obtained at baseline and following 8 weeks of either risperidone or placebo in a double-blind parallel group design. Risperidone treatment was associated with significant increases in relative metabolic rate in the striatum, cingulate gyrus, the prefrontal cortex, especially in the orbital region, and the thalamus. Four of 9 patients who received risperidone showed clinical improvement (CGI score of 1 or 2 at 8 weeks) while none of the 6 patients who received placebo showed improvement. Patients with low relative metabolic rates in the striatum and high relative metabolic rates in the anterior cingulate gyrus were more likely to show a clinical response. These metabolic predictors of clinical response are consistent with earlier PET studies showing similar prediction when either neuroleptics or serotonin reuptake inhibitor treatments are administered individually. Our results are consistent with a frontostriatal circuit change related to both dopaminergic and serotonergic systems and with the presence of psychopharmacological subtypes within OCD.

AB - We studied 15 nondepressed patients with obsessive-compulsive disorder (OCD) who were nonresponders to serotonin reuptake inhibitors with an additive trial of risperidone. Positron emission tomography with 18F- deoxyglucose and magnetic resonance imaging was obtained at baseline and following 8 weeks of either risperidone or placebo in a double-blind parallel group design. Risperidone treatment was associated with significant increases in relative metabolic rate in the striatum, cingulate gyrus, the prefrontal cortex, especially in the orbital region, and the thalamus. Four of 9 patients who received risperidone showed clinical improvement (CGI score of 1 or 2 at 8 weeks) while none of the 6 patients who received placebo showed improvement. Patients with low relative metabolic rates in the striatum and high relative metabolic rates in the anterior cingulate gyrus were more likely to show a clinical response. These metabolic predictors of clinical response are consistent with earlier PET studies showing similar prediction when either neuroleptics or serotonin reuptake inhibitor treatments are administered individually. Our results are consistent with a frontostriatal circuit change related to both dopaminergic and serotonergic systems and with the presence of psychopharmacological subtypes within OCD.

KW - F-deoxyglucose

KW - Caudate

KW - Cingulate gyrus

KW - Obsessive-compulsive disorder

KW - Putamen

UR - http://www.scopus.com/inward/record.url?scp=33744950727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744950727&partnerID=8YFLogxK

U2 - 10.1159/000093342

DO - 10.1159/000093342

M3 - Article

VL - 53

SP - 157

EP - 168

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 3

ER -